Bibliographic Details
| Title: |
Prostate cancer screening in low- and middle-income countries: the Mexican case. |
| Alternate Title: |
Tamizaje para cáncer de próstata en países de bajos y medianos ingresos: el caso mexicano. |
| Authors: |
Lajous, Martin1,2 mlajous@insp.mx, Cooperberg, Matthew R.3,4, Rider, Jennifer5,6, Manzanilla-García, Hugo Arturo7, Gabilondo-Navarro, Fernando Bernardo8, Rodríguez-Covarrubias, Francisco Tomás8, López-Ridaura, Ruy1, Torres-Sánchez, Luisa Elvira1, Mohar, Alejandro9 |
| Source: |
Salud Pública de México. jul-ago2019, Vol. 61 Issue 4, p542-544. 3p. |
| Subjects: |
MIDDLE-income countries, EARLY detection of cancer, PROSTATE cancer, PROSTATE-specific antigen, COST control |
| Geographic Terms: |
MEXICO |
| Abstract (English): |
Prostate-specific antigen (PSA)-based early detection for prostate cancer is the subject of intense debate. Implementation of organized prostate cancer screening has been challenging, in part because the PSA test is so amenable to opportunistic screening. To the extent that access to cancer screening tests increases in low- and middle-income countries (LMICs), there is an urgent need to thoughtfully evaluate existing and future cancer screening strategies to ensure benefit and control costs. We used Mexico's prostate cancer screening efforts to illustrate the challenges LMICs face. We provide five considerations for policymakers for a smarter approach and implementation of PSA-based screening. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): |
El uso del Antígeno Prostático Específico (APE) para tamizaje para cáncer de próstata sigue siendo tema de amplio debate. La implementación de estrategias de tamiz organizado de cáncer de próstata ha sido un reto en parte porque la prueba de APE se presta para detección oportunista. A medida que aumenta el acceso a las pruebas de detección de cáncer en los países de ingresos bajos y medianos (PIBM), existe la necesidad urgente de evaluar cuidadosamente las estrategias actuales y futuras de detección oportuna de cáncer para garantizar su beneficio y controlar sus costos. Utilizamos los esfuerzos de tamizaje de cáncer de próstata de México para ilustrar los retos para PIBM. Ofrecemos cinco consideraciones dirigidas a tomadores de decisión que permitan contar con estrategias racionales de implementación de tamizaje para cáncer de próstata basado en el uso de APE. [ABSTRACT FROM AUTHOR] |
|
Copyright of Salud Pública de México is the property of Instituto Nacional de Salud Publica and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
MedicLatina |
